39results about How to "Eliminate drug resistance" patented technology

The invention relates to an anti-helicobacter pylori oral preparation. The anti-helicobacter pylori oral preparation is prepared from, by weight, 6-12 parts of anti-helicobacter pylori egg yolk immunoglobulin, 2-5 parts of lactoferrin and 2-5 parts of chlorophyll in barley green. According to the anti-helicobacter pylori oral preparation, helicobacter pylori infection can be cured under the condition that no antibiotic is used, therefore, the cure rate is increased, the possibility that a pathogen generates drug resistance and the potential of relapse after curing are eliminated, and meanwhile the adverse effect rate is greatly decreased.

The invention provides a chemical processing method of coal chemical industry recycled circulating cooling water. An agentia is composed of composite scale and corrosion inhibitor which is composed of 9-11 parts of polyepoxysuccinic acid, 18-22 parts of 2-phosphonobutane-1,2,4-tricarboxylic acid, 19-21 parts of methylene phosphonic acid, 25-35 parts of dirt dispersion agent, 1-3 parts of benzotriazole, and 9-18 parts of deionized water. First, adding polyepoxysuccinic acid into the 2-phosphonobutane-1,2,4-tricarboxylic acid, placing the polyepoxysuccinic acid and the 2-phosphonobutane-1,2,4-tricarboxylic acid in a container and evenly mixing, sequentially adding the methylene phosphonic acid, the dirt dispersion agent and the deionized water into the container, then stirring for 25-35 minutes, keeping the temperature at 20-35 DEG C, then adding the benzotriazole, continuously stirring for 30-60 minutes and keeping the temperature at 20-35 DEG C, and then, the composite scale and corrosion inhibitor is obtained. Dosage of the composite scale and corrosion inhibitor is 10mg / L, based on middle warmer strengthening water, total phosphorus of the circulating water is controlled to be 4-7mg / L, and a concentration ratio is controlled to be 5.0-6.0 times. The method further comprises sterilization and algae removing process and optimization of the circulating water.

The present application provides an application of a drug in the preparation of a drug for the treatment of brain metastases-related diseases, wherein the drug includes at least one TRPV4 agonist capable of promoting calcium ion influx of TRPV4 signaling channels, the brain metastases and Related diseases include brain metastases, diseases arising during the formation of brain metastases, complications and sequelae caused by brain metastases, and diseases related to brain metastases. Applying the above-mentioned medicine to the preparation of medicines for treating diseases related to brain metastases can play a significant anti-tumor effect through a clear mechanism of action, with good therapeutic effects and good application prospects.